Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study

BACKGROUND: Bezlotoxumab is approved for prevention of recurrence of Clostridioides difficile infection (CDI) in adults receiving standard of care (SoC) therapy based on findings from MODIFY clinical trials. However, utilization practices and validation of trial results in the real world are limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Hengel, Richard L, Ritter, Timothy E, Nathan, Ramesh V, Van Anglen, Lucinda J, Schroeder, Claudia P, Dillon, Ryan J, Marcella, Stephen W, Garey, Kevin W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186524/
https://www.ncbi.nlm.nih.gov/pubmed/32363211
http://dx.doi.org/10.1093/ofid/ofaa097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186524/
https://www.ncbi.nlm.nih.gov/pubmed/32363211
http://dx.doi.org/10.1093/ofid/ofaa097

Ejemplares similares